Hi Wanderdog,I think this is the third time you speak of „mid...

Hi Wanderdog,

I think this is the third time you speak of „mid trial readouts by November“ as this should be „standard clinical practice“.

Sorry for sounding so totally clueless, but what exactly do you mean by this?

And what kind of communication around such mid trial readouts should one expect? A press release saying „everything‘s fine. We proceed with the trial“? Or rather „BCVA so far is x for sham and y for sozinibercept“?

What irritates me further is that after so many years (enrollment started Mar 2021) you are the very first person bringing up the topic of mid trial read outs. I have not seen any analyst nor the company ever bringing up this point.

And further, I do not remember Roche or Novartis having done such mid trial readouts for Vabysmo or Beovu.

If I missed this topic for pure negligence, I beg your pardon. But your expectation of such mid trial readouts, for the moment, really irritates me. As I can‘t make up the context…

So thx a lot for some more meat on the bone from your side.